Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Restorbio, Inc. was a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to target the biology of aging and improve the lives of patients with aging-related diseases. Their primary focus was on the TORC1 pathway, with a lead candidate RTB101. In late 2020, Restorbio merged with Adicet Bio, Inc., and the combined company now operates under the Adicet Bio name, focusing on allogeneic gamma delta T cell therapies for cancer.
Served as the central hub for corporate operations, clinical development, research strategy, and administrative functions prior to the company's merger.
Located in a prominent office building in Boston, providing modern facilities suitable for a biopharmaceutical company's executive and research planning needs. Specific architectural details are not widely publicized.
As a clinical-stage biotech, the culture likely emphasized scientific innovation, a fast-paced environment, collaboration, and a strong focus on research milestones and patient outcomes.
The Boston headquarters was pivotal for Restorbio's strategic decision-making, investor relations, and coordination of its clinical trials aimed at addressing aging-related diseases.
Restorbio's operations were primarily centered in the United States, focusing on research, clinical development, and corporate activities. While their therapeutic targets had global relevance, their direct physical presence was concentrated in the US. Clinical trials for its programs may have involved international sites.
200 Berkeley Street, 18th Floor
Boston
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Restorbio' leadership includes:
Restorbio has been backed by several prominent investors over the years, including:
In the 12 months leading up to its merger in September 2020, Restorbio saw key executive changes, including a new VP appointment and a notable departure, as it navigated its clinical programs and eventual combination with Adicet Bio. The CEO also transitioned to lead the new combined entity.
Discover the tools Restorbio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its merger, Restorbio, Inc. likely used common corporate email formats. Standard patterns for biopharmaceutical companies include first initial followed by last name ([flast]@domain.com) or first name followed by a period then last name ([first].[last]@domain.com).
f[last]@restorbio.com or [first].[last]@restorbio.com
Format
jsmith@restorbio.com or jane.doe@restorbio.com
Example
65%
Success rate
GlobeNewswire (Adicet Bio Press Release) • September 29, 2020
Restorbio, Inc. announced the completion of its merger with Adicet Bio, Inc. The combined company, operating as Adicet Bio, focuses on the development of allogeneic gamma delta T cell therapies for cancer and began trading on Nasdaq under the ticker symbol 'ACET'....more
FierceBiotech (reporting on company announcement) • November 15, 2019
Restorbio announced that its lead drug candidate, RTB101 (an oral TORC1 inhibitor), did not meet the primary endpoint in a Phase 3 clinical trial aimed at preventing respiratory tract infections in elderly patients. This outcome significantly impacted the company's stock and future strategic plans....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Restorbio, are just a search away.